Literature DB >> 14962951

Patients with rheumatoid arthritis in clinical care.

J S Smolen, D Aletaha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14962951      PMCID： PMC1754912          DOI： 10.1136/ard.2003.012575

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  76 in total

1.  World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Authors:  M Boers; P Tugwell; D T Felson; P L van Riel; J R Kirwan; J P Edmonds; J S Smolen; N Khaltaev; K D Muirden
Journal:  J Rheumatol Suppl       Date:  1994-09

2.  Development of a disease activity score based on judgment in clinical practice by rheumatologists.

Authors:  D M van der Heijde; M van 't Hof; P L van Riel; L B van de Putte
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

3.  The relationship between serial measures of disease activity and outcome in rheumatoid arthritis.

Authors:  A B Hassell; M J Davis; P D Fowler; S Clarke; J Fisher; M F Shadforth; P W Jones; P T Dawes
Journal:  Q J Med       Date:  1993-09

4.  Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.

Authors:  G A Wells; P Tugwell; G R Kraag; P R Baker; J Groh; D A Redelmeier
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

5.  Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.

Authors:  M A van Leeuwen; D M van der Heijde; M H van Rijswijk; P M Houtman; P L van Riel; L B van de Putte; P C Limburg
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

Review 6.  Joint erosions and patients with early rheumatoid arthritis.

Authors:  D M van der Heijde
Journal:  Br J Rheumatol       Date:  1995-11

7.  Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic.

Authors:  E J Tunn; P A Bacon
Journal:  Br J Rheumatol       Date:  1993-02

8.  A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity.

Authors:  G Stucki; M H Liang; S Stucki; P Brühlmann; B A Michel
Journal:  Arthritis Rheum       Date:  1995-06

9.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06

10.  The lag time between onset of symptoms and diagnosis of rheumatoid arthritis.

Authors:  K W Chan; D T Felson; R A Yood; A M Walker
Journal:  Arthritis Rheum       Date:  1994-06
View more
  15 in total

1.  MRI bone oedema predicts eight year tendon function at the wrist but not the requirement for orthopaedic surgery in rheumatoid arthritis.

Authors:  S Zheng; E Robinson; S Yeoman; N Stewart; J Crabbe; J Rouse; F M McQueen
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

2.  Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials.

Authors:  D Aletaha; M M Ward
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

Review 3.  What is the clinical relevance of erosions and joint space narrowing in RA?

Authors:  Siri Lillegraven; Désirée van der Heijde; Till Uhlig; Tore K Kvien; Espen A Haavardsholm
Journal:  Nat Rev Rheumatol       Date:  2012-01-17       Impact factor: 20.543

Review 4.  Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects.

Authors:  Josef S Smolen; Kurt Redlich; Jochen Zwerina; Daniel Aletaha; Günter Steiner; Georg Schett
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

5.  Gait changes precede overt arthritis and strongly correlate with symptoms and histopathological events in pristane-induced arthritis.

Authors:  Markus H Hoffmann; Rudolf Hopf; Birgit Niederreiter; Heinz Redl; Josef S Smolen; Günter Steiner
Journal:  Arthritis Res Ther       Date:  2010-03-11       Impact factor: 5.156

6.  Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Kath D Watson; Mark Lunt; Katie McGrother; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2010-05-05       Impact factor: 7.580

Review 7.  [Measuring disease activity for rheumatoid arthritis].

Authors:  D Aletaha; T Stamm; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

8.  The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound.

Authors:  Maxime Dougados; Valérie Devauchelle-Pensec; Jean François Ferlet; Sandrine Jousse-Joulin; Maria-Antonietta D'Agostino; Marina Backhaus; Jacques Bentin; Gérard Chalès; Isabelle Chary-Valckenaere; Philip Conaghan; Richard J Wakefield; Fabien Etchepare; Frédéric Etcheparre; Philippe Gaudin; Walter Grassi; Désirée van der Heijde; Xavier Mariette; Esperanza Naredo; Marcin Szkudlarek
Journal:  Ann Rheum Dis       Date:  2012-06-07       Impact factor: 19.103

9.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

10.  DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.

Authors:  Bert Vander Cruyssen; Stijn Van Looy; Bart Wyns; Rene Westhovens; Patrick Durez; Filip Van den Bosch; Eric M Veys; Herman Mielants; Luc De Clerck; Anne Peretz; Michel Malaise; Leon Verbruggen; Nathan Vastesaeger; Anja Geldhof; Luc Boullart; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2005-07-08       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.